{"ATC Code":"M - Musculo-skeletal system","Abbreviation":"","Aliases":["Benzidamine","Benzindamine","Bencidamina","Benzydaminum","Benzidamina","Apo-Benzydamine","benzydamide","1-Benzyl-3-(3-(dimethylamino)propoxy)-1H-indazole","C 1523","Difflam"],"Biological Half-Life":"Approximately 13 h after oral administration, with a terminal half life of about 7.7 h.","CAS":"642-72-8","ChEBI":"CHEBI:94563","ChEMBL":"CHEMBL12610","ChemicalClasses":["benzamide"],"Chirality":"achiral","Classes":null,"Dosing Info":[],"Drug Indication":"Available predominantly as a liquid mouthwash, oromucosal spray, or topical cream, benzydamine is most frequently employed as a locally acting analgesic and anti-inflammatory treatment for the relief of painful inflammatory conditions.   When formulated as a mouthwash or spray, benzydamine may be used to treat traumatic conditions like pharyngitis following tonsillectomy or the use of a naso-gastric tube, inflammatory conditions like pharyngitis, aphthous ulcers and oral ulceration due to radiation therapy, dentistry operations and procedures, or more general conditions like sore throat, sore tongue, sore gums, mouth ulcers, or discomfort caused by dentures.   When used as a topical cream, benzydamine may be employed to relieve symptoms associated with painful inflammatory conditions of the muscolo-skeletal system including acute inflammatory disorders such as myalgia and bursitis or traumatic conditions like sprains, strains, bruises, sore muscles, stiff joints, or even the after-effects of fractures.","DrugClasses":[],"EINECS":"211-388-8","EliminationHalfLife":"13 hours","European Community (EC) Number":"211-388-8","FullSalts":["Benzydamine hydrochloride","Benzydamine salicylate"],"HMDB ID":"HMDB0249061","HeavyAtomCount":23,"Human Drugs":"Pharmaceuticals","IUPACName":"3-(1-benzylindazol-3-yl)oxy-N,N-dimethylpropan-1-amine","InChI":"InChI=1S/C19H23N3O/c1-21(2)13-8-14-23-19-17-11-6-7-12-18(17)22(20-19)15-16-9-4-3-5-10-16/h3-7,9-12H,8,13-15H2,1-2H3","InChIKey":"CNBGNNVCVSKAQZ-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)","Melting Point":"320°F","MolecularFormula":"C\u003csub\u003e19\u003c/sub\u003eH\u003csub\u003e23\u003c/sub\u003eN\u003csub\u003e3\u003c/sub\u003eO","MolecularWeight":"309.4 g/mol","Pharmacodynamics":"Benzydamine is a non-steroidal anti-inflammatory drug (NSAID) designed to elicit local anesthetic and analgesic effects mainly for the mouth and throat. It specifically acts on the local mechanisms of inflammation such as pain, oedema, or granuloma. Typically applied topically, the drug demonstrates anti-inflammatory activity reducing oedema as well as exudate and granuloma formation. Moreover, benzydamine exhibits analgesic properties and local anaesthetic activity if pain is caused by an inflammatory condition. Benzydamine can be absorbed into the oral mucosa and intact skin. Once absorbed in the local area of pain or inflammation, benzydamine binds selectively to local inflamed tissues, usually allowing it to act with few adverse systemic effects. On average a period of 2 to 4 hours is necessary for the substance to reach peak plasma concentration.   Benzydamine can be synthesized with the reaction of the N-benzyl derivative from methyl anthranilate with nitrous acid to give N-nitoso derivative. This is next reduced by sodium thiosulfate to give transient hydrazine. This hydrazine can then undergo spontaneous internal hydrazide formation. Treating this resultant enolate with 3-chloro-1-dimethylamkino propane ultimately yields benzydamine.","PrevSalts":["hydrochloride","salicylate"],"PubChemId":12555,"Record Description":["Benzydamine is a member of the class of indazoles carrying benzyl and 3-(dimethylamino)propyl groups at positions 1 and 3 respectively. A locally-acting nonsteroidal anti-inflammatory drug that also exhibits local anaesthetic and analgesic properties. It has a role as a central nervous system stimulant, a non-steroidal anti-inflammatory drug, a hallucinogen, a local anaesthetic and an analgesic. It is a member of indazoles, an aromatic ether and a tertiary amino compound. It is a conjugate base of a benzydamine(1+).","Benzydamine (also known as Tantum Verde or Difflam), available as the hydrochloride salt, is a locally-acting nonsteroidal anti-inflammatory drug (NSAID) with local anaesthetic and analgesic properties. It is used topically for pain relief and anti-inflammatory treatment of the mouth, throat, or muscoskeletal system.  Although the indazole analogue benzydamine is a non-steroidal anti-inflammatory drug (NSAID), it has various physicochemical properties and pharmacologic activities that are different from those of traditional aspirin-like NSAIDs but facilitate benzydamine's mechanism of action as an effective locally-acting NSAID with local anaesthetic and analgesic properties. Moreover, unlike aspirin-like NSAIDs which are acids or metabolised to acids, benzydamine is in fact a weak base.","BENZYDAMINE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) and has 4 approved and 2 investigational indications.","A benzyl-indazole having analgesic, antipyretic, and anti-inflammatory effects. It is used to reduce post-surgical and post-traumatic pain and edema and to promote healing. It is also used topically in treatment of RHEUMATIC DISEASES and INFLAMMATION of the mouth and throat.","Benzydamine is a member of the class of indazoles carrying benzyl and 3-(dimethylamino)propyl groups at positions 1 and 3 respectively. A locally-acting nonsteroidal anti-inflammatory drug that also exhibits local anaesthetic and analgesic properties. It has a role as a central nervous system stimulant, a non-steroidal anti-inflammatory drug, a hallucinogen, a local anaesthetic and an analgesic. It is a member of indazoles, an aromatic ether and a tertiary amino compound. It is a conjugate base of a benzydamine(1+)."],"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Benzydamine","Name":"Benzydamine","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q793143","Name":"Benzydamine","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB09084","Name":"Benzydamine","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/12555","Name":"Benzydamine","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL12610","Name":"Benzydamine","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:94563","Name":"Benzydamine","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=642-72-8","Name":"Benzydamine","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0249061","Name":"Benzydamine","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/D07516","Name":"Benzydamine","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/4O21U048EF","Name":"Benzydamine","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID7047859","Name":"Benzydamine","Sub":false}]}],"SMILES":"CN(C)CCCOC1=NN(C2=CC=CC=C21)CC3=CC=CC=C3","Salts":["hydrochloride","salicylate"],"SaltsAcidCount":[1,0],"SaltsAmineCount":[1,1],"SaltsUNII":["K2GI407R4Q","APY0XA4O95"],"Scheduling":[{"gov":"Brazil","schedule":"C1 substance"},{"gov":"United Kingdom","schedule":"P and prescription only substance"},{"gov":"European Union","schedule":"OTC substance"}],"Solubility":"Miscible","StoreUNII":["4O21U048EF"],"StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="67.005mm" version="1.2" viewBox="0 0 153.693 67.005" width="153.693mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#3050F8" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="68.0" stroke="none" width="154.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="152.639" x2="145.318" y1="8.439" y2="16.568"/>
                  
            <line class="bond" id="mol1bnd2" x1="143.668" x2="147.147" y1="23.544" y2="34.258"/>
                  
            <line class="bond" id="mol1bnd3" x1="139.13" x2="127.533" y1="19.059" y2="16.593"/>
                  
            <line class="bond" id="mol1bnd4" x1="127.533" x2="117.334" y1="16.593" y2="27.917"/>
                  
            <line class="bond" id="mol1bnd5" x1="117.334" x2="102.428" y1="27.917" y2="24.747"/>
                  
            <line class="bond" id="mol1bnd6" x1="102.428" x2="94.888" y1="24.747" y2="33.118"/>
                  
            <line class="bond" id="mol1bnd7" x1="88.6" x2="77.322" y1="35.299" y2="32.9"/>
                  
            <g class="bond" id="mol1bnd8">
                        
                <line x1="77.322" x2="72.787" y1="32.9" y2="22.707"/>
                        
                <line x1="74.374" x2="70.559" y1="32.273" y2="23.698"/>
                      
                <line class="hi" stroke="#3050F8" x1="72.787" x2="75.0545" y1="22.707" y2="27.8035"/>
                <line class="hi" stroke="#3050F8" x1="70.559" x2="72.4665" y1="23.698" y2="27.985500000000002"/>
            </g>
                  
            <line class="bond" id="mol1bnd9" x1="67.794" x2="59.305" y1="19.327" y2="20.216"/>
                  
            <line class="bond" id="mol1bnd10" x1="55.157" x2="52.794" y1="24.384" y2="35.47"/>
                  
            <g class="bond" id="mol1bnd11">
                        
                <line x1="52.794" x2="39.595" y1="35.47" y2="43.09"/>
                        
                <line x1="52.793" x2="42.034" y1="38.286" y2="44.497"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd12" x1="39.595" x2="39.6" y1="43.09" y2="58.338"/>
                  
            <g class="bond" id="mol1bnd13">
                        
                <line x1="39.6" x2="52.803" y1="58.338" y2="65.967"/>
                        
                <line x1="42.038" x2="52.804" y1="56.931" y2="63.151"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd14" x1="52.803" x2="66.002" y1="65.967" y2="58.347"/>
                  
            <g class="bond" id="mol1bnd15">
                        
                <line x1="66.002" x2="65.997" y1="58.347" y2="43.098"/>
                        
                <line x1="63.563" x2="63.559" y1="56.939" y2="44.506"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd16" x1="52.794" x2="65.997" y1="35.47" y2="43.098"/>
                  
            <line class="bond" id="mol1bnd17" x1="77.322" x2="65.997" y1="32.9" y2="43.098"/>
                  
            <line class="bond" id="mol1bnd18" x1="53.095" x2="45.78" y1="17.366" y2="9.234"/>
                  
            <line class="bond" id="mol1bnd19" x1="45.78" x2="30.872" y1="9.234" y2="12.395"/>
                  
            <g class="bond" id="mol1bnd20">
                        
                <line x1="26.157" x2="30.872" y1="26.896" y2="12.395"/>
                        
                <line x1="24.273" x2="28.118" y1="24.803" y2="12.979"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd21" x1="26.157" x2="11.248" y1="26.896" y2="30.057"/>
                  
            <g class="bond" id="mol1bnd22">
                        
                <line x1="1.054" x2="11.248" y1="18.716" y2="30.057"/>
                        
                <line x1="3.808" x2="12.12" y1="18.133" y2="27.379"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd23" x1="1.054" x2="5.769" y1="18.716" y2="4.215"/>
                  
            <g class="bond" id="mol1bnd24">
                        
                <line x1="20.678" x2="5.769" y1="1.054" y2="4.215"/>
                        
                <line x1="19.806" x2="7.653" y1="3.732" y2="6.308"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd25" x1="30.872" x2="20.678" y1="12.395" y2="1.054"/>
                  
            <path class="atom" d="M144.38 22.213h-.72l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .357 .024 .732v2.739h-.566v-4.9h.714l2.608 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.769h.577v4.9z" id="mol1atm2" stroke="none"/>
                  
            <path class="atom" d="M94.488 36.068q-.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q-.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM90.624 36.068q.0 .923 .387 1.458q.393 .53 1.221 .53q.839 .0 1.22 -.53q.387 -.535 .387 -1.458q.0 -.929 -.387 -1.453q-.381 -.524 -1.208 -.524q-.834 .0 -1.227 .524q-.393 .524 -.393 1.453z" fill="#FF0D0D" id="mol1atm7" stroke="none"/>
                  
            <path class="atom" d="M73.068 21.427h-.72l-2.619 -4.066h-.03q.012 .239 .03 .596q.023 .357 .023 .732v2.738h-.565v-4.899h.714l2.608 4.054h.029q-.005 -.107 -.017 -.327q-.012 -.221 -.024 -.477q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" id="mol1atm9" stroke="none"/>
                  
            <path class="atom" d="M57.913 23.014h-.721l-2.619 -4.066h-.03q.012 .239 .03 .596q.024 .357 .024 .732v2.738h-.566v-4.899h.715l2.607 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.024 -.477q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" id="mol1atm10" stroke="none"/>
                
            <line class="hi" id="mol1bnd1" stroke="#3050F8" x1="145.318" x2="148.9785" y1="16.568" y2="12.5035"/>
            <line class="hi" id="mol1bnd2" stroke="#3050F8" x1="143.668" x2="145.4075" y1="23.544" y2="28.901000000000003"/>
            <line class="hi" id="mol1bnd3" stroke="#3050F8" x1="139.13" x2="133.3315" y1="19.059" y2="17.826"/>
            <line class="hi" id="mol1bnd6" stroke="#FF0D0D" x1="94.888" x2="98.658" y1="33.118" y2="28.9325"/>
            <line class="hi" id="mol1bnd7" stroke="#FF0D0D" x1="88.6" x2="82.961" y1="35.299" y2="34.0995"/>
            <line class="hi" id="mol1bnd9" stroke="#3050F8" x1="67.794" x2="63.549499999999995" y1="19.327" y2="19.771500000000003"/>
            <line class="hi" id="mol1bnd9" stroke="#3050F8" x1="59.305" x2="63.549499999999995" y1="20.216" y2="19.771500000000003"/>
            <line class="hi" id="mol1bnd10" stroke="#3050F8" x1="55.157" x2="53.9755" y1="24.384" y2="29.927"/>
            <line class="hi" id="mol1bnd18" stroke="#3050F8" x1="53.095" x2="49.4375" y1="17.366" y2="13.3"/>
        </g>
          
    </g>
    
</svg>
","Title":"Benzydamine","UNII":"4O21U048EF","Wikidata":"Q793143","Wikipedia":"Benzydamine","XLogP":3.9}